Literature DB >> 29049111

Risk Management for Opioid Prescribing in the Treatment of Patients With Pain From Cancer or Terminal Illness: Inadvertent Oversight or Taboo?

David J Copenhaver1, Nicolas B Karvelas, Scott M Fishman.   

Abstract

As the United States experiences an epidemic of prescription drug abuse, and guidelines on safe practices in prescribing opioids in chronic pain have subsequently emerged from professional organizations and governmental agencies, limited guidance exists for prescribers of opioids to treat pain in patients with cancer or terminal illness. Patients with active cancer or terminal illness often have pain and are frequently prescribed opioids and other controlled substances. Current studies suggest that patients with cancer have similar rates of risk for misuse, abuse, and addiction as the general public. Moreover, palliative care and hospice programs appear poorly prepared for assessing or managing patients with aberrant behaviors or evidence of drug abuse. Further research and professional consensus are needed to help address the challenges associated with misuse, abuse, and addiction in patients with cancer and terminal illness.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29049111     DOI: 10.1213/ANE.0000000000002463

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

1.  Long-Term Opioid Therapy in Older Cancer Survivors: A Retrospective Cohort Study.

Authors:  Rahul Shah; Lin-Na Chou; Yong-Fang Kuo; Mukaila A Raji
Journal:  J Am Geriatr Soc       Date:  2019-04-26       Impact factor: 5.562

2.  Gaps in the Use of Long-Acting Opioids Within Intervals of Consecutive Days Among Cancer Outpatients Using Electronic Pill Caps.

Authors:  Salimah H Meghani; Amelia L Persico; Jeffrey Fudin; George J Knafl
Journal:  Pain Med       Date:  2021-03-18       Impact factor: 3.750

3.  Chinese Version of the Psychological Inflexibility in Pain Scale for Cancer Patients Reporting Chronic Pain.

Authors:  Chan-Juan Xie; Xiang-Hua Xu; Mei-Jun Ou; Yong-Yi Chen
Journal:  Cancer Nurs       Date:  2021 May-Jun 01       Impact factor: 2.760

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.